Increased lipids often occur in patients with nephrotic syndrome, especially hypercholesterolemia is more common, often accompanied by increased triglycerides, and some patients do not have high triglycerides. If hyperlipidemia persists, it can increase the viscosity of the blood, which can easily lead to thrombosis, cardiovascular disease, and aggravate the damage to the kidneys. Increased lipids in patients with nephrotic syndrome are mainly due to the fact that patients lose a large amount of protein from the urine, causing hypoproteinemia, which induces disorders of lipid metabolism and the formation of hyperlipidemia. If, after treatment, proteinuria is rapidly reduced or even disappears, hypoproteinemia is corrected, and the increased lipids will naturally drop to normal levels, there is no need to use lipid-lowering drugs at this time. If elevated lipids persist, appropriate lipid-lowering drugs should be selected for treatment. If the elevated blood lipids are mainly cholesterol, with or without triglyceride elevation, you can use statins, such as pravastatin, trade name Praglum, Meperlane; simvastatin, trade name Shujiazhi, Simcoe; lovastatin, trade name Meperlane. If the elevated blood lipids are mainly triglycerides, you should use fibrates, such as Fenofibrate, trade name Lippincott, and Gemfibrozil, trade name Novocain, and its extended-release type trade name Lipocompound. The side effects of statins are mainly liver function damage and muscle damage, so pay attention to the review of liver function and muscle enzymes during taking the drug. Do not use statins in patients with active hepatitis. Long-term use of statins should be carefully chosen from antibiotic classes, which can easily cause lysis of the transverse muscle, such as erythromycin, clarithromycin, antifungal drugs, and neomycin, cyclosporine, etc. Statins should also not be used in women who are pregnant or breastfeeding. Betablockers can cause stones, so they should not be used by patients with gallstones or gallbladder disease.